FreeAir

PopularMy Searches

Back

List View

Most Popular

Programs

There has been some controversy as to whether inflammation and neurodegeneration in MS may be two independent disease processes and, therefore, whether MS-related neurodegeneration may occur in the absence of inflammation, particularly in patients with progressive disease. A recent study analyzed the interdependence between inflammation, neurodegeneration, and disease progression in the various stages of MS, focusing especially on progressive disease. Join John DeLuca, PhD, as he discusses the results with Claudia Lucchinetti, MD, a member of the study's research team, and explores the implications of this work for the development of new therapies.
Inflammation and Neurodegeneration in Multiple Sclerosis
Although a variety of factors have been identified that predict the quality of life in patients with MS, these predictors have not been examined simultaneously to determine their relative importance. Two experts in the field, Dr. Timothy Vollmer and Dr. Ralph Benedict, discuss recent research identifying the primary predictors of physical and mental health QOL in patients with MS, as well as the most significant factors in predicting employability/vocational status-findings that have important implications for the management of patients with MS. Predictors of Health-Related Quality of Life and Vocational Status in Multiple Sclerosis
Multiple sclerosis (MS) affects 400,000 Americans and is the leading nontraumatic cause of neurological disability in young adults. Although MS is progressive, it is not fatal, and patients generally have a normal lifespan. However, progressive disability imposes increasing limitations and reduced quality of life for these patients. Newly released consensus guidelines offer neurologists and primary care physicians direction to improve the differential diagnosis and develop strategies to facilitate early and accurate diagnosis of MS. A number of factors must be considered when selecting a treatment regimen for patients with MS, including variations in clinical and MRI evidence of disease. The discovery and broad application of MRI in medicine has led to an increased awareness of the number of patients with incidental white matter pathology in the CNS. The natural history or evolution of such individuals with respect to their risk of developing MS is unclear, but a need for further studies on this subject and physician awareness is essential for progression of disease therapy in MS. In this two-part neuroscienceCME Journal Club series, the authors will translate their research and provide insights and application to clinical practice. Featured Article: Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler. 2008;14:1157-1174. neuroscienceCME - Management of Multiple Sclerosis, Part 1 of 2: Differential Diagnosis - A Consensus Approach
Multiple sclerosis (MS) affects 400,000 Americans and is the leading nontraumatic cause of neurological disability in young adults. Although MS is progressive, it is not fatal, and patients generally have a normal lifespan. However, progressive disability imposes increasing limitations and reduced quality of life for these patients. Newly released consensus guidelines offer neurologists and primary care physicians direction to improve the differential diagnosis and develop strategies to facilitate early and accurate diagnosis of MS. A number of factors must be considered when selecting a treatment regimen for patients with MS, including variations in clinical and MRI evidence of disease. The discovery and broad application of MRI in medicine has led to an increased awareness of the number of patients with incidental white matter pathology in the CNS. The natural history or evolution of such individuals with respect to their risk of developing MS is unclear, but a need for further studies on this subject and physician awareness is essential for progression of disease therapy in MS. In this two-part neuroscienceCME Journal Club series, the authors will translate their research and provide insights and application to clinical practice. Featured Article: Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009;72:800-805. neuroscienceCME - Management of Multiple Sclerosis, Part 2 of 2: MRI Abnormalities - The Radiologically Isolated Syndrome
This audio podcast reports on some of the most important new MS research presented at the ECTRIMS annual meeting, held October 13-16, 2010, in Gothenburg, Sweden. Listen as James D. Bowen, MD, talks about new findings that enhance understanding of MS pathophysiology, testing, neuroregeneration, and cognition. Fred D. Lublin, MD, reviews presentations on emerging and current MS therapies.
Highlights of the European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
This CME/CE on-demand audio podcast features presentations from a recent live lecture and workshop, held in Seattle, WA, that focused on the management of multiple sclerosis (MS) in the primary care setting. Join Kate E. Kennedy, MN, ARNP, and Sylvia M. Lucas, MD, PhD, who have particular expertise in caring for patients with MS, as they discuss practical strategies on diagnosis and disease management that primary care clinicians can immediately incorporate into practice. Recognizing and Treating Multiple Sclerosis in the Primary Care Setting
The lastest news about multiple sclerosis research and services in the Greater Delaware Valley area MS Society: Greater Delaware Valley
The audio science podcasts from Bayer turn the spotlight on research and knowledge.

Our approximately 5-minute reports outline how Bayer is conducting research into new therapeutic options to treat cancer and multiple sclerosis, what’s special about carbon nanotubes and the contribution that Bayer makes to safeguarding harvests.
Bayer Audio research - The science podcast from Bayer
I am a author and artist living with Multiple Sclerosis, MS for short. I am currently in a clinical trial for fingolimod, which is a pill. I like helping people and making people laugh. Penelope Smith | Blog Talk Radio Feed
one woman's journey with multiple sclerosis Don't Believe Everything They Say

Media:English Navigation:English

Earn Cash | Publish | Advertise | Device Partners | Contact Us | DMCA | Help | About FreeAir

Copyright © 2023 FreeAir.tv, Inc. ® All rights reserved.

Use of this Web site constitutes acceptance of the Terms of Use, Cloud TV Terms and Conditions, FreeAir.tv Agreements, FreeAir.tv Internet Agreements, Purchase Agreement and Privacy Policy

2.062823.live.2